/Investor DB

REDMILE — 2021 Investments

7 investments dated 2021 · listed companies and verified rows first · show all

Invivydinvivyd.comin𝕏NASDAQ: IVVDApr 2021 · $336M

Invivyd is a biopharmaceutical company that develops antibody-based product candidates for the prevention and treatment of serious viral infectious diseases, combining viral surveillance and predictive modeling with antibody engineering.

BiotechHealthtechWaltham, US

Tillman U. Gerngross(Executive Officer, Director)Marc Elia(Founder)inLynn Connolly(Executive Officer)inEric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)inRebecca Dabora(Executive Officer)in

Co-investorsBain Capital Life SciencesForesite CapitalGV (Google Ventures)MRL Ventures FundPremji InvestRA Capital+6 more

GRO Biosciencesgrobio.comin𝕏Nov 2021 · $25M✓ verified

GRObio (GRO Biosciences) develops protein therapeutics using non-standard amino acids (NSAAs) via its GRO platform, aiming to improve protein potency, stability, and function.

BiotechDeep TechHealthtechCambridge, US

Daniel J Mandell(Chief Executive Officer)Tracey Lodie(Executive Officer)inChristopher Gregg(Director)

BoardMing Fang(Director)Bruce Beutel(Director)Dan Becker(Director)

Co-investorsLeaps by BayerAlumni VenturesDigitalis VenturesDreamers VCOS FundRising Tide+3 more

Home Bioscienceshomebiosciences.cominNov 2021 · $15M✓ verified

Home Biosciences was a venture builder in Continental Europe dedicated to creating and scaling biotech companies through an asset-centric, hub-and-spoke model, working with academics and scientists on drug discovery and molecular profiling projects.

AI & Machine LearningBiotechHealthtech

David Schilansky(Co-founder & Non-executive Chairman)inMagali Richard(Co-founder)in

Co-investorsSofinnova Partners

Attralusattralus.comin𝕏Sep 2021 · $116M

Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.

BiotechHealthtechSouth San Francisco, US

Jonathan Wall(Executive Officer)inSpencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)inBenson Fong(Executive Officer)Rahul Kakkar(Director)inGreg Bell(Executive Officer)

Co-investorsAlpha Wave GlobalBioBritLifeSci Venture PartnersvenBio PartnersJanus Henderson InvestorsSamsara BioCapital+2 more

Mnemo Therapeuticsmnemo-tx.comJun 2021

Mnemo Therapeutics is a Paris-based clinical-stage biotech developing cell therapies using its EnfiniT epigenetic antigen discovery platform to target tumor-specific antigens for CAR-T therapies.

Co-investorsSofinnova PartnersAlexandriaCasdin Capital

Sphere Fluidicsspherefluidics.comOct 2021 · $40M

Sphere Bio develops instruments, consumables, and reagents based on picodroplet microfluidic technology for single cell isolation and analysis.

BiotechDeep TechHardware

Co-investors24 HaymarketQVenturesProvidence Investment Company LimitedSofinnova Partners

Thriveworksthriveworks.comin𝕏Jul 2021

Thriveworks provides therapy and psychiatric medication management services, helping clients find providers and book sessions, with insurance accepted.

Digital HealthHealthtechMedia & EntertainmentMental HealthWellness & Fitness

Anthony Centore(Executive Officer, Director)AJ Centore(Founder)inDaniel Frogel, MDinJon Santemma(Executive Officer, Director)Terry Wang(Director)David Kim(Director)

Co-investorsRA CapitalRogue Insight CapitalTRANSFORMATION CAPITALWellington ManagementFidelity Investments

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.